ShEEP request for next generation sequencing system

ShEEP 请求下一代测序系统

基本信息

  • 批准号:
    9906671
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-01 至 2020-09-30
  • 项目状态:
    已结题

项目摘要

The requested sequencing equipment is state-of-the-art sequencing machine, versatile, and will be used by all funded VA investigators at the VABHS. This is Illumina NextSeq-550 Sequencing System with 10X genomics controller to make single-cell-libraries. Our researchers at VABHS investigate diverse fields of research including cancer (myeloma & colorectal) and neuroscience (Alzheimer's, sleep, CTE, TBI & PTSD) as well as other fields of research (kidney, spinal cord, stem cells, coagulation, & alcoholism) that are aimed at aiding veterans. Currently, VA-funded projects have specifically outlined procedures using NGS sequencing and microarray scanning instruments, but they must use non-VA facilities to perform their VA research. We describe that VA investigators do not currently have the requested sequencing equipment at any VABHS research facility is a major need for this equipment. The equipment will also allow for exciting new developments for VA investigators research projects and give new opportunities for collaborations between VA and non-VA investigators. Obtaining this equipment can also strengthen new funding proposals and lead to collaborations including those that will complement genetic wide-association studies such as the Million Veteran Program. Lastly, having this equipment on site will allow us to attract and retain the best possible basic and clinical scientific talent in the world on topics that will serve our veterans. Drs. Zielinski and Prabhala will be responsible for being fully informed of the equipment operation and maintenance and will ensure that users are trained in flow cell cleaning and general- purpose cleaning.
所要求的测序设备是最先进的测序机,用途广泛,将被所有人使用 资助 VABHS 的 VA 调查员。这是具有 10X 基因组学的 Illumina NextSeq-550 测序系统 控制器来制作单细胞文库。我们 VABHS 的研究人员调查了不同的研究领域,包括 癌症(骨髓瘤和结直肠癌)和神经科学(阿尔茨海默病、睡眠、CTE、TBI 和 PTSD)以及其他领域 旨在帮助退伍军人的研究(肾脏、脊髓、干细胞、凝血和酗酒)。 目前,VA 资助的项目已经具体概述了使用 NGS 测序和微阵列的程序 扫描仪器,但他们必须使用非 VA 设施来进行 VA 研究。我们描述了 VA 研究人员目前在任何 VABHS 研究机构中都没有所需的测序设备 主要需要这种设备。该设备还将为 VA 调查人员带来令人兴奋的新进展 研究项目,并为 VA 和非 VA 研究人员之间的合作提供新的机会。获得 该设备还可以加强新的融资提案并促成合作,包括那些将 补充遗传广泛关联研究,例如百万退伍军人计划。最后,有了这个装备 现场将使我们能够吸引并留住世界上最优秀的基础和临床科学人才 这将为我们的退伍军人服务。博士。 Zielinski 和 Prabhala 将负责充分了解 设备操作和维护,并将确保用户接受流通池清洁和一般方面的培训 目的清洁。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nikhil C. Munshi其他文献

Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia.
硼替佐米和利妥昔单抗联合治疗复发和/或难治性华氏巨球蛋白血症的 II 期试验。
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    45.3
  • 作者:
    I. Ghobrial;J. Matous;S. Padmanabhan;A. Badros;R. Schlossman;S. Chuma;R. Leduc;Marybeth Nelson;Kelly O’Connor;A. Sam;B. Harris;J. Soumerai;D. Warren;A. Birner;Nikhil C. Munshi;S. Treon;K. Anderson;P. Richardson
  • 通讯作者:
    P. Richardson
A TCR-like CAR T Cell Therapy for the Treatment of MZB1 Positive Multiple Myeloma and Other B-Cell Malignancies
  • DOI:
    10.1182/blood-2024-208607
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Elena Maroto Martin;Yingjie Zhao;Sara Mangesh Kolhatkar;Roberto Garcia-Vicente;Mubin Tarannum;Mehmet K. Samur;Mariateresa Fulciniti;Rizwan Romee;Jianzhu Chen;Nikhil C. Munshi
  • 通讯作者:
    Nikhil C. Munshi
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
  • DOI:
    10.1016/j.leukres.2023.107074
  • 发表时间:
    2023-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Michel Delforge;Paula Rodríguez Otero;Nina Shah;Olga Moshkovich;Julia Braverman;Devender S. Dhanda;Sally Lanar;Jennifer Devlen;Matthew Miera;Heather Gerould;Timothy B. Campbell;Nikhil C. Munshi
  • 通讯作者:
    Nikhil C. Munshi
OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma
  • DOI:
    10.1016/s2152-2650(21)02107-8
  • 发表时间:
    2021-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Annamaria Gulla;Eugenio Morelli;Mehmet K Samur;Cirino Botta;Megan Johnstone;Giada Bianchi;Mariateresa Fulciniti;Leona Yamamoto;Rao Prabhala;Kenneth Wen;Paul G. Richardson;Yu-Tzu Tai;Dharminder Chauhan;Teru Hideshima;Nikhil C. Munshi;Kenneth Anderson
  • 通讯作者:
    Kenneth Anderson
P-057: A helicase “ASCC3” is coupled to FEN1-mediated genomic instability and cancer cell proliferation
  • DOI:
    10.1016/s2152-2650(21)02191-1
  • 发表时间:
    2021-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Chengcheng Liao;Shidai Mu;Jiangning Zhao;Subodh Kumar;Leutz Buon;Srikanth Talluri;Mehmet K Samur;Masood Shammas;Nikhil C. Munshi
  • 通讯作者:
    Nikhil C. Munshi

Nikhil C. Munshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nikhil C. Munshi', 18)}}的其他基金

ShEEP Request for BD FACSAria Fusion Cell Sorting Flow Cytometer
ShEEP 请求 BD FACSAria 融合细胞分选流式细胞仪
  • 批准号:
    9361304
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
分子调控增强抗骨髓瘤反应
  • 批准号:
    8597935
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Molecular Manipulation to Enhance Anti-Myeloma Response
分子操作增强抗骨髓瘤反应
  • 批准号:
    10486218
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
分子调控增强抗骨髓瘤反应
  • 批准号:
    8963449
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSE
分子调控增强抗骨髓瘤反应
  • 批准号:
    8332546
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Integrative Oncogenomics of Multiple Myeloma
多发性骨髓瘤的综合肿瘤基因组学
  • 批准号:
    10226185
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Core 1: Administrative and Communication Core
核心 1:行政和沟通核心
  • 批准号:
    10226186
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Integrative Oncogenomics of Multiple Myeloma
多发性骨髓瘤的综合肿瘤基因组学
  • 批准号:
    8326575
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Administrative and Communication Core
行政和沟通核心
  • 批准号:
    8566800
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Innate and Adaptive Anti-Myeloma Immunity
先天性和适应性抗骨髓瘤免疫
  • 批准号:
    8249891
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了